India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Sun Pharmaceutical Industries Ltd. closed 14.19% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

Discover the Sun Pharma Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Sun Pharmaceutical Industries Ltd. closed 13.62% below its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

LEQSELVI has shown rapid results in clinical trials, with one-third of patients regaining nearly full scalp hair by Week 24.

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

As part of the agreement, Incyte has granted Sun Pharma a limited, non-exclusive license to US Patent Nos. 9,662,335 and ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...